Bayesian Analysis to Refine East Asian Subgroup Estimates in the CLEAR Trial (Lenvatinib Plus Pembrolizumab vs. Sunitinib) for Advanced Renal Cell Carcinoma. |

This study aimed to refine estimates of lenvatinib plus pembrolizumab (Len/Pembro) efficacy in East Asian patients with advanced renal cell carcinoma (aRCC) in the CLEAR trial using Bayesian borrowing from Western Europe and North America (WENA), and to assess safety while preser

Medical Literature · Updated 2026-08-07

← Back to articles

This standalone article is served from the ClinicLens content archive.

If the embedded page does not load in your browser, open it directly.